Literature DB >> 10946553

[Treatment strategy for cervical node metastasis from squamous cell carcinoma of the oropharynx].

T Nigauri1, S Kamata, K Kawabata, K Hoki, H Mitani, S Yoshimoto, H Yonekawa, K Miura, T Beppu, M Uchida.   

Abstract

The purpose of this study is to ascertain the role of neck surgery and radiation therapy for cervical lymph node metastasis in oropharyngeal cancer patients. We reviewed 217 previously untreated patients with squamous cell carcinoma of the oropharynx who were treated at the Cancer Institute Hospital in Tokyo between 1971 and 1995. The N stage distribution was; N0: 83(38.2%), N1: 42(19.4%), N2a: 23(10.6%), N2b: 27(12.4%), N2c: 33(15.2%), and N3: 9(4.2%). A predominance of cervical node metastases in level II and III was revealed and there were no skip metastases outside of level II and III. The control rate of cervical metastasis for each N stage was; N0: 96.9%, N1: 90.0%, N2a: 76.5%, N2b: 62.5%, N2c: 50.0%, and N3: 0%. Definitive irradiation provided sufficient treatment for small nodes, when the primary tumor growth was well controlled by radiation therapy. Neck dissection was necessary for more advanced neck metastases. Selective limited neck dissection (level II and III) is recommended for N0 and N1 patients, and modified or classical RND is considered to be better for most cases with N2 and N3.

Entities:  

Mesh:

Year:  2000        PMID: 10946553     DOI: 10.3950/jibiinkoka.103.803

Source DB:  PubMed          Journal:  Nihon Jibiinkoka Gakkai Kaiho        ISSN: 0030-6622


  2 in total

1.  PET-CT staging of the neck in cancers of the oropharynx: patterns of regional and retropharyngeal nodal metastasis.

Authors:  Marcie Tauzin; Amy Rabalais; Joseph L Hagan; Charles G Wood; Robert L Ferris; Rohan R Walvekar
Journal:  World J Surg Oncol       Date:  2010-08-16       Impact factor: 2.754

2.  Extent of surgical intervention in case of N0 neck in head and neck cancer patients: an analysis of data collection of 39 hospitals.

Authors:  A A Dünne; B J Folz; C Kuropkat; J A Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-09-09       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.